Does the inclusion of the cost and burden of adverse drug reactions associated with drug-resistant TB treatment affect the incremental cost-effectiveness of new treatment regimens?
Share this work:
Join Afribary to Unlock Full Content
- Access thousands of Academic, business and legal documents
- Share your quality papers, documents with a global community
- Build your professional profile. Publish your papers and reach thousands of scholars. Get cited and reviewed